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one HLA-DRB1 allele (recipient HLA, A 24:02/33:03, B 48:01/51:01, Cw 08:03/14:02, DRB1*09:01/09:01; donor HLA, A 24:02/33:03, B 48:01/51:01 Cw 08:03/14:02 DRB1*09:01/11:01). The conditioning regimen included total-body irradiation (TBI) (2 Gy on day −1), total-lymphoid irradiation (TLI) (3 Gy on day 0), fludarabine (Flu) (30 mg/m 2 /day on days −5, −4, −3, and −2), cyclophosphamide (CY) (25 mg/kg/day on days −5, −4, −3, and −2), and ATG (Thymoglobulin, 2.5 mg/kg/day on day −5 and −4).
Prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus (from day −1) and short-term methotrexate (5 mg/m 2 /day on days 1, 3, and 6). Both donor and recipient were EBV positive before transplantation. The neutrophil count surpassed 500/µl on day 16 after BMT. She developed a high fever, systemic lymphadenopathy, and hepatosplenomegaly on day 38. The WBC count was 3790/µl with 4% leukemic lymphocytes that were positive for EBV-encoded mRNA, as demonstrated by in situ hybridization and donor type cells by chimerism analysis. Flow cytometry (FCM) of peripheral-blood lymphocytes revealed that virtually all B cells expressed CD19 + , CD20 + and Igκ. The EBV-DNA copy number was 23970/ml of blood and 48000/ml of serum. EBV clonality was confirmed by Southern blotting using the EBV terminal-repeat probe and an IgH PCR assay. sIL-2R level was 1523 U/ml and anti-EBV antibody titer was as follows: EBV anti-VCA IgG, 80×; EBV anti-VCA IgM, <10×; EBV anti EA-DR IgG, <10×; EBV-anti EBNA, 10×. Although a bone-marrow aspiration (BMA) was not performed because of her severe condition on day 38, BMA study showed 11% leukemic lymphocytes in bone marrow on day 40 after rituximab treatment. She was therefore diagnosed as having EBV-associated leukemic lymphoma.
Following discontinuation of tacrolimus on day 38, we treated the patient with rituximab (375 mg/m 2 /day on days 38, 42, 47, 54, and 86), cidofovir (5 mg/kg/day on days 41 and 48), and DLI (1 × 10 6 CD3 + cells/kg on day 46), after the approval by the Institutional Review Board of Kanazawa University. No renal impairment was observed after the cidofovir treatment. The blood CD19 + atypical lymphocyte count decreased to 0/µl on day 48, and her systemic lymphadenopathy resolved. However, the CD8 + HLA-DR + lymphocyte count increased to 10230/µl on day 53. Detection of EBV-specific cytotoxic T cells was performed according to the previous report 1 .The FCM analysis using an HLA-A24 tetramer revealed 1% of the CD8 + T cells to be EBV-specific cytotoxic T cells, which were markedly increased compared with EBV-specific CD8 + T cells in pre-BMT blood (0.1%, day −10), post-rituximab treatment blood (0.2%, day 42), and the donor lymphocyte inoculum (0.1%) ( Figure 1 ).
Cytomegalovirus (CMV)-specific CD8 + T cells also increased from 0.1% (pre-transplant) to 1.5% after the DLI. CMV antigenemia that occurred on day 31 was no longer detected after day 56. EBV-DNA in blood decreased from 13860 copies/ml on day 45, to 203 copies/ml on day 52, 204 copies/ml on day 95, and became undetectable on day 116. Grade I (skin stage 1) acute GVHD developed 6 days after DLI but was remitted without additional treatments. No signs of chronic GVHD were observed.
Although there is persistent B-cell lymphocytopenia (60-120/µl) with hypogammaglobulinemia (IgG levels 220-470 mg/dl), the patient is alive without relapse of either EBV-PTLD or AA as of September, 2015. lymphocytes and chimerism analysis revealed that they were donor type cells. A bone-marrow study was not performed because of his severe condition. The clonality of CD19 + /CD20 + cells of his peripheral blood was confirmed by the predominant Igκ expression using FCM. The EBV-DNA copy number was 600,000/ml of blood. He was diagnosed to have EBV-associated leukemic lymphoma, and was treated with DLI on day 53 (5 × 10 5 CD3 + cells/kg) and on day 58 (1 × 10 6 CD3 + cells/kg) in addition to rituximab (375 mg/m 2 on day 57). Tacrolimus was discontinued from day 55. Despite these treatments, the number of atypical lymphocytes increased to 4082/µl accounting for 13% of WBC. FCM of peripheral blood on day 59 revealed no CD19 + /CD20 + cells and an increase in the CD8 + cell count to 8095/µl. His liver and renal injuries deteriorated and he died of multiple organ failure on day 59. Any symptoms of GVHD were not observed during his clinical course. 
Other similar and contrasting cases in the literature

Discussion
EBV-PTLD is rare, but is considered to be one of the most serious complications after allogeneic stem-cell transplantation. The fatality rate of EBV-PTLD has been reported to be 50%-92% [4] [5] [6] [7] . Before the rituximab era, unmanipulated DLI was the only effective treatment for EBV-PTLD, although DLI was not potent enough to cure EBV-PTLD and often induced severe GVHD. The effect of DLI is believed to be mediated by T cells specific to EBV specific epitopes such as EBV-BMLF1, EBV-BRLF1, and EBV-EBNA3A 8 . Although Comoli et al showed that EBV-specific T-cell frequency was restored by EBV-specific CTLs therapy for EBV-PTLD to levels comparable with controls, they evaluated EBV-specific T-cell frequency indirectly using IFN-γ secretion from lymphocytes by ELISPOT assay or flow cytometry 3 . This is, to our knowledge, the first report to confirm the increase of EBV-specific cytotoxic T cells using EBV-tetramers after DLI and rituximab treatment directly. Muramatsu et al reported that EBV-tetramer-positive CD8 + cells were detected in the peripheral blood of a patient after radiation and rituximab treatment for EBV-PTLD 9 . In our case, EBV-specific T cells that had been present in the peripheral blood before rituximab treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load. This clinical course clearly shows that EBV-specific T cells played a substantial role in eradicating EBV-PTLD.
We experienced four leukemic EBV-PTLD cases (0.5%) among the 797 who received allogeneic stem-cell transplantation (alloSCT) from 1991 to 2013 at our institutes 10, 11 (Table 1 ). All four patients received ATG-conditioning regimens and it is well known that these regimens induce EBV diseases post-alloSCT due to the level of immunosuppression 12 . Patriarca et al demonstrated that CD4 + T-cell counts <50/µl at day +30 post-alloSCT were significantly associated with an increased risk of high-load EBV-DNAemia (>10000 copies/ml) in alloSCT patients in whom 68% received ATG in their conditioning regimen 13 . Our case 1 patient's CD4 + T-cell counts were also < 50/µl at day +30 post-alloSCT. Two of the four patients with leukemic EBV-PTLD were treated with DLI or DLI plus rituximab but did not show treatment response; both died due to progressive disease. In the latter case (Case 2) the delayed rituximab administration might have been the cause of the progressive disease. Because monotherapy with rituximab is reported to rescue 63% patients with PTLD 14 , we expected that rituximab therapy would not be able to cure a fulminant EBV-PTLD as seen in our case even in combination with DLI. Cidofovir, a monophosphate nucleotide analogue of cytosine that inhibits viral DNA polymerase, is effective in treating various kinds of viral infections due to adenovirus 15 , BK virus 16 , and EBV [17] [18] [19] . Although the addition of cidofovir to rituximab-DLI therapy may have helped the patient to overcome such a disastrous condition without obvious adverse effects, there is little evidence to suggest therapeutic efficacy against EBV 14, 20 . It is therefore reasonable to consider EBV-CTL therapy if available to patients who progress under rituximab treatment and DLI 20 .
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